In a greenhouse outside Manchester, a small team is trying to rewrite the part of a plant that most gene-editing companies politely ignore: the organelles. Not the nucleus, where CRISPR has spent the last decade making headlines, but the chloroplasts and mitochondria, the tiny power units that photosynthesize sugar and burn it for energy. Cytotrait Ltd., a 2023 spinout from the University of Manchester, has built a system it calls MOSS, the Mutant Organelle Selection System, that it says can drive edited copies of an organelle genome to dominance inside a plant cell, a state biologists call homoplasmy [AgTechNavigator, 2026/03/10]. In March 2026 the company closed a £3M seed round (roughly $4M) led by Northern Gritstone with participation from the UK Innovation & Science Seed Fund [Tech.eu, 2026/03/09].
The pitch is unusually concrete for a pre-commercial biotech. A typical plant cell carries dozens to hundreds of chloroplast genome copies. Edit one and you have a rounding error. Cytotrait says MOSS removes the unedited copies and lets the edited ones propagate, which is what unlocks what the company calls ultra-high trait expression, and it claims to have demonstrated this in two crops already [AgTechNavigator, 2026/03/10]. The targets it is naming publicly read like a staples shopping list: wheat, maize, potato, and canola [The Bae HQ, 2026/03]. Founder Dr. Junwei Ji is listed as Co-Founder and Executive Director, and the company emerged through the University of Manchester Innovation Factory and the NG Studios venture builder [University of Manchester].
The bet
Cytotrait is selling a platform, not a seed. The business model, as described in the seed announcements, is B2B: license the MOSS toolkit to crop developers and agribusinesses that want traits the nuclear-editing toolbox struggles to deliver, things like herbicide tolerance routed through the chloroplast, improved photosynthetic efficiency, or cytoplasmic male sterility for hybrid breeding [Tech Funding News]; [Startupmag]. Organelle editing has a quietly attractive regulatory wrinkle in some jurisdictions because chloroplast DNA is maternally inherited in most crops, which limits pollen-mediated transgene flow, a perennial complaint about first-generation GM crops. Whether regulators in the EU, UK, and US treat MOSS-edited plants as gene-edited (lighter touch) or transgenic (heavier touch) will matter enormously for the addressable market, and it is not yet settled.
Seed round (£M) | 3 | £M
Seed round (USD equivalent) | 4.03 | $M
Crops demonstrated to date | 2 | crops
Crops named as targets | 4 | crops
Why it could be big
The macro case writes itself, which is usually a warning sign, except here the unit economics of agriculture really are the binding constraint. A one percent yield lift on global wheat (roughly 800 million tonnes a year) is eight million tonnes, about the annual wheat consumption of the Netherlands and Belgium combined (estimated). If MOSS can deliver trait expression levels that nuclear edits cannot match, even modest gains in photosynthesis or stress tolerance compound into very large tonnage. Northern Gritstone, the Manchester-Leeds-Sheffield deep-tech fund spun out of the northern English universities, is exactly the kind of patient capital this thesis needs, and UKI2S has a long track record backing university spinouts through the awkward years between bench and field trial [Prolific North].
The other reason to pay attention is that organelle engineering has been technically stuck for decades. Chloroplast transformation works reliably in tobacco and almost nowhere else commercially important. If Cytotrait's claim of a species-agnostic selection system holds up in independent hands, that is a genuine unlock for a sub-field that has been promising breakthroughs since the 1990s. Two crops demonstrated is not four, and four is not forty, but it is more than most organelle-editing groups have shown.
Team and traction
Dr. Junwei Ji leads the company as Co-Founder and Executive Director, with the spinout structured through the University of Manchester Innovation Factory [University of Manchester]. The £3M seed is explicitly framed as the capital to move MOSS from proof-of-concept in two species into the named staple crops [iGrow News, 2026]. NG Studios, Northern Gritstone's venture-building arm, is on the cap table as accelerator, which usually implies meaningful operational support on hiring and commercial development rather than a passive check.
What the bears say, and the bullish answer
The credible concern is not the science, it is the field-to-farm gap. Plenty of trait platforms have shown striking greenhouse data and then spent a decade and nine figures getting a single trait through field trials, regulatory clearance, and into a commercial seed line. AgTechNavigator's coverage notes the company is still pre-field for its named target crops [AgTechNavigator, 2026/03/10], and £3M does not fund a regulatory dossier on its own. The bullish answer is that Cytotrait is not trying to be a seed company. As a platform licensor, it can let larger partners (the Cortevas, Bayers, Syngentas of the world) shoulder the field and regulatory cost in exchange for trait royalties, which is the same wedge Inari and Tropic have used to raise considerably larger rounds. Whether the major ag incumbents bite is the question the next 18 months will answer.
What to watch
Three things over the next year. First, a peer-reviewed publication or independent replication of the MOSS homoplasmy claim in a cereal, ideally wheat or maize, would move this from interesting to important. Second, a named partnership with a Tier 1 seed company would validate the licensing model and almost certainly precede a Series A. Third, watch how UK and EU regulators classify organelle-edited crops under the post-Brexit Precision Breeding Act and the EU's evolving NGT rules. A favorable read could compress Cytotrait's path to revenue by years.
Back of envelope: at £3M and a typical UK biotech burn of roughly £80k per FTE per year fully loaded (estimated), the seed funds something like a 12 to 15 person team for two years, enough to push MOSS into two more crops and generate the data package a Series A would need. That is tight but not unreasonable for a platform play with a clear next milestone.
The incumbent Cytotrait must beat: Inari Agriculture, the Flagship-backed multispecies seed design company that has raised north of $700M and is already shipping edited soy and corn into commercial channels. Inari edits the nucleus. Cytotrait is betting the organelle is the better address. Both cannot be right at the same dose.